Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | VNN1 | O95497 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8160823 | 0.83 | KDM5A (0.46) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL15264280 | 0.81 | KDM5A (0.44) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL6015105 | 0.81 | VNN1 (0.46) | KDM5AF10VNN1NPC1RAB9A | |
| SCHEMBL10074929 | 0.80 | KDM5A (0.43) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL18701762 | 0.79 | VNN1 (0.46) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL19001328 | 0.79 | EPHX2 (0.44) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL10074641 | 0.79 | POLB (0.46) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL10074405 | 0.79 | NPC1 (0.44) | KDM5AF10VNN1KMT2ANPC1 | |
| SCHEMBL10232786 | 0.78 | KDM5A (0.41) | KDM5AF10VNN1PIK3CDMMP13 | |
| SCHEMBL4516164 | 0.77 | L3MBTL1 (0.52) | TP53MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | KDM5A 3421/4885F10 4279/4885VNN1 3483/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | KDM5A 3421/4885F10 4279/4885VNN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.